Accessibility Menu
Integra LifeSciences Stock Quote

Integra LifeSciences (NASDAQ: IART)

$15.65
(1.2%)
+0.19
Price as of October 23, 2025, 1:21 p.m. ET

KEY DATA POINTS

Current Price
$15.69
Daily Change
(1.2%) +$0.19
Day's Range
$15.26 - $15.75
Previous Close
$15.46
Open
$15.46
Beta
1.04
Volume
377,016
Average Volume
1,223,045
Market Cap
1.2B
Market Cap / Employee
$15.46M
52wk Range
$11.06 - $27.13
Revenue
-
Gross Margin
0.56%
Dividend Yield
N/A
EPS
-$6.53
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Integra LifeSciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
IART-19.44%-68.49%-20.63%+270%
S&P+14.5%+93.32%+14.09%+1,096%

Integra LifeSciences Company Info

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$415.61M-0.6%
Gross Profit$226.00M-8.6%
Gross Margin54.38%-4.7%
Market Cap$953.53M-58.5%
Market Cap / Employee$0.22M0.0%
Employees4.4K-17.5%
Net Income-$484.07M-3803.2%
EBITDA$73.29M1.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$217.91M1.2%
Accounts Receivable$284.51M2.4%
Inventory465.110.3%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.39B-29.7%
Short Term Debt$627.55M1516.1%

Ratios

Q2 2025YOY Change
Return On Assets-12.93%-13.5%
Return On Invested Capital3.36%-0.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$11.23M-205.0%
Operating Free Cash Flow$8.92M-77.9%

Valuation

MetricQ4 2023Q1 2024Q2 2024YoY Change
Price to Earnings51.6469.9398.75-
Price to Book0.921.151.100.63-56.44%
Price to Sales0.891.091.040.58-59.70%
Price to Tangible Book Value-1.78-2.17-2.23-1.24-74.87%
Price to Free Cash Flow TTM45.2338.3036.5270.1150.21%
Enterprise Value to EBITDA62.0834.4448.0636.86-33.10%
Free Cash Flow Yield2.2%2.6%2.7%1.4%-33.43%
Return on Equity-0.4%-0.4%-1.9%-38.9%-2747.30%
Total Debt$1.99B$1.98B$2.02B$2.01B0.21%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.